C Plater-Zyberk

Summary

Affiliation: Micromet AG
Country: Germany

Publications

  1. pmc GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice
    C Plater-Zyberk
    Micromet AG, Staffelseestr 2, Munich D 81477, Germany
    Ann Rheum Dis 66:452-7. 2007
  2. doi Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model
    C Plater-Zyberk
    Micromet AG, Munich, Germany
    Ann Rheum Dis 68:721-8. 2009
  3. doi The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated
    Christine Plater-Zyberk
    Micromet Inc 6707 Democracy Blvd, Bethesda, MD 20817, USA
    Transpl Immunol 25:133-40. 2011
  4. pmc Transfer of type II collagen-induced arthritis from DBA/1 to severe combined immunodeficiency mice can be prevented by blockade of Mac-1
    P C Taylor
    Kennedy Institute of Rheumatology, London, UK
    Immunology 88:315-21. 1996
  5. ncbi Amelioration of arthritis in two murine models using antibodies to oncostatin M
    C Plater-Zyberk
    Geneva Biomedical Research Institute, Switerland
    Arthritis Rheum 44:2697-702. 2001
  6. pmc Interferon beta stimulates interleukin 1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts
    G Palmer
    Division of Rheumatology, University Hospital, and Department of Pathology, University of Geneva School of Medicine, Geneva, Switzerland
    Ann Rheum Dis 63:43-9. 2004

Collaborators

Detail Information

Publications6

  1. pmc GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice
    C Plater-Zyberk
    Micromet AG, Staffelseestr 2, Munich D 81477, Germany
    Ann Rheum Dis 66:452-7. 2007
    ..In this model, the pathogenic contribution of tumour necrosis factor (TNF)alpha is minor and is expressed only on joint swelling, whereas cartilage proteoglycan depletion is independent of this cytokine...
  2. doi Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model
    C Plater-Zyberk
    Micromet AG, Munich, Germany
    Ann Rheum Dis 68:721-8. 2009
    ..In the present study, the simultaneous blockade of both pathways in a mouse model for chronic arthritis was investigated to identify whether this double blockade provides a superior therapeutic efficacy...
  3. doi The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated
    Christine Plater-Zyberk
    Micromet Inc 6707 Democracy Blvd, Bethesda, MD 20817, USA
    Transpl Immunol 25:133-40. 2011
    ..The characteristics of MT204, displaying linear pharmacokinetics, half-life in the range expected for a human IgG, benign safety profile and signs of efficacy, warrant further development of this antibody for therapy...
  4. pmc Transfer of type II collagen-induced arthritis from DBA/1 to severe combined immunodeficiency mice can be prevented by blockade of Mac-1
    P C Taylor
    Kennedy Institute of Rheumatology, London, UK
    Immunology 88:315-21. 1996
    ..Our findings support the hypothesis that cells expressing Mac-1 play an important role in the induction and maintenance of joint damage in collagen-induced arthritis...
  5. ncbi Amelioration of arthritis in two murine models using antibodies to oncostatin M
    C Plater-Zyberk
    Geneva Biomedical Research Institute, Switerland
    Arthritis Rheum 44:2697-702. 2001
    ....
  6. pmc Interferon beta stimulates interleukin 1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts
    G Palmer
    Division of Rheumatology, University Hospital, and Department of Pathology, University of Geneva School of Medicine, Geneva, Switzerland
    Ann Rheum Dis 63:43-9. 2004
    ..Interferon (IFN) beta displays anti-inflammatory and immunosuppressive activity and has been considered for the treatment of rheumatoid arthritis (RA). Information about the effects of this molecule on joint cells is scarce, however...